TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02072018
Drug: H-100
Normalized name: steareth-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
Study: NCT02072018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
Study: NCT00708123
Drug: Placebo toothpaste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride free toothpaste (0 ppm F)
Study: NCT03864575
Drug: Celecoxib 400 mg
Normalized name: celecoxib 400 MG
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 400 mg/day in combination with nivolumab fixed dose
Study: NCT01231594
Drug: GSK1120212
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT01231594
Drug: Other approved anti-cancer agent
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT03008850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly allocated to one of two groups:~Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.~Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally.
Study: NCT01012375
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg capsule, oral dose
Study: NCT01012375
Drug: AZD1446
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg capsule, oral dose
Study: NCT01012375
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsule, oral dose
Study: NCT01057407
Drug: ASP1585
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01868880
Drug: betablocker titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
Study: NCT03991143
Drug: ATH3G10
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT03991143
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT01723059
Drug: Standard Triple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: for 10 days
Study: NCT01723059
Drug: Sequential Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: total 10 days
Study: NCT03219580
Drug: Normal Saline Flush, 0.9% Injectable Solution
Normalized name: Normal Saline Flush, 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
Study: NCT01422122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one table spoon Syrup per day
Study: NCT00385502
Drug: EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nail lacquer applied daily for 48 weeks
Study: NCT00272142
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00272142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03159091
Drug: Rengalin
Normalized name: Sengalia catechu wood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT03159091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration.
Study: NCT00788372
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
Study: NCT03790345
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjuvant daily treatment with 200mg of pyridoxine
Study: NCT04632758
Drug: WX-0593 Tablets
Normalized name: WX-554
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets, 60 mg→180mg, QD
Study: NCT02258451
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 6 cycles of saline injection
Study: NCT01018628
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
Study: NCT03483753
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure \<65 mmHg after fluid replacement. Continuous infusion of the drug at doses ranging from 0.1 mcg / kg / min to 1.0 mcg / kg / min.
Study: NCT05103878
Drug: BT051 700mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 700mg BT051
Study: NCT05103878
Drug: BT051 1500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 1500mg BT051
Study: NCT05103878
Drug: BT051 3500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 3500mg BT051
Study: NCT00520923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
Study: NCT00520923
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
Study: NCT04066491
Drug: M7824
Normalized name: M7824
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received intravenous infusion of M7824 at a dose of 2400 milligrams (mg), once every 3 weeks (Q3W) 2 years (in case of Complete Response), otherwise until criterion pre-sepcified in protocol for discontinuation is met, in combination with intravenous infusion of Gemcitabine and Cisplatin at a dose of 1000 milligram per meter square (mg/m\^2) and 25 mg/m\^2 respectively on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks.
Study: NCT04066491
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received intravenous infusion of M7824 matched placebo, once every 3 weeks (Q3W) until 2 years (in case of CR), otherwise until crtiterion pre-sepcified in protocol for discontinuation is met.
Study: NCT01931007
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
Study: NCT01053871
Drug: midazolam with fentanyl
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: conscious sedation using midazolam with fentanyl
Study: NCT00270777
Drug: adrenaline, promethazine, hydrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05050071
Drug: Allium Sativum
Normalized name: ALLIUM SATIVUM WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sixty-six permanent mature necrotic incisors associated with apical periodontitis in male children were selected. Teeth were randomly divided into three groups (n=22) according to intra canal medications used; group I: Ca OH2, group II: garlic extract and group III: mixture of Ca OH2 and garlic extract. After access preparation, four microbiological samples (S) were as follows; (S1): were taken before canal instrumentation and irrigation. (S2): after cleaning and shaping, Then, the third samples (S3) and forth samples (S4) were taken after placement of the tested intracanal medications into the corresponding canals, for 7 and 14 days respectively. Total DNA was extracted from microbiological samples and relative quantitive real time PCR reactions were done to quantify the relative gene expression levels (FC) for Streptococcus and Enterococcus faecalis species.
Study: NCT00625209
Drug: placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
Study: NCT00633256
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
Study: NCT00309881
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00625209
Drug: hydrocortisone and fludrocortisone and placebo
Normalized name: fludrocortisone and antiinfectives
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
Study: NCT03584919
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients received oral doxycycline 100 milgrams bid for 15 days
Study: NCT00876395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus placebo was administered in a continuous oral daily dosing of 10 mg (two 5-mg tablets).
Study: NCT00625209
Drug: recombinant human activated protein C and hydrocortisone and fludrocortisone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
Study: NCT00005785
Drug: GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00089661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
Study: NCT03227471
Drug: TEZ/IVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEZ/IVA fixed-dose combination for oral administration.
Study: NCT03227471
Drug: Matched Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo.
Study: NCT00349375
Drug: Fenofibrate/Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fenofibrate 145mg and Simvastatin 20mg
Study: NCT00349375
Drug: Fenofibrate/Simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fenofibrate and Simvastatin 40 mg
Study: NCT00349375
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg
Study: NCT02681536
Drug: HMG
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00418990
Drug: Multivitamin/Mineral supplements
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03757325
Drug: DNL747
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNL747
Study: NCT03757325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02903901
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg liquid Melatonin IR-SL at 7 pm for 1 week
Study: NCT02903901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg liquid placebo at 7 pm for 1 week
Study: NCT01901575
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
Study: NCT03101540
Drug: Omega-3 PUFA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.
Study: NCT00957528
Drug: Testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly im injections of 100 mg testosterone enanthate.
Study: NCT00957528
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly IM injections of sesame oil.
Study: NCT01110473
Drug: ABT-348
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Study: NCT01110473
Drug: ABT-348
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
Study: NCT01110473
Drug: ABT-348
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
Study: NCT00543010
Drug: MK0767
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04940104
Drug: Botox Injectable Product
Normalized name: Botox Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox is a well known neurotoxin that is derived from the bacterium clostridium botulinium. Its therapeutic applications are variable and well documented, alongside its cosmetic applications. There are seven known serotypes of Botox, from A to G, but only two types; A \&B, are available for medical and cosmetic uses.
Study: NCT01237730
Drug: Tailored antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
Study: NCT00794963
Drug: Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.
Study: NCT00496457
Drug: Experimental
Normalized name: WA-001 Experimental Soil Surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
Study: NCT01021956
Drug: STAKEL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two Drug Light Interval (DLI).Second stage(dose confirmation)will be only initiated at a dose level in which an effect has been seen at week 1 and there is a maximum of one Dose Limiting Toxicity (DLT) out of three subject at week 5.
Study: NCT01620931
Drug: RO5469754
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ascending doses, iv or sc
Study: NCT01620931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses, iv or sc
Study: NCT00496457
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Capsules of PBO per day before noon meal
Study: NCT04090008
Drug: Saline dressing
Normalized name: Dermagran Zinc-Saline Dressing 8x4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline is used for dressing of the ulcer twice a week
Study: NCT02463409
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 hour infusion of IV theophylline
Study: NCT00483301
Drug: ABI-007(Abraxane)
Normalized name: PICEA ABIES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage
Study: NCT00338039
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m\^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
Study: NCT00360594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 pills (666mg) for 1998mg/day
Study: NCT03118232
Drug: Iodophor (10% povidone-iodine)
Normalized name: iodophors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.
Study: NCT03702985
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 625mg/m2 bid Monday-Friday per week
Study: NCT02947672
Drug: Intraperitoneal Dexamesathone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02466711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind Placebo will be delivered three times by injection during the course of the study
Study: NCT03045861
Drug: GSK2838232
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.
Study: NCT00905931
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: starch
Study: NCT04089592
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intravenous fentanyl at 2mcg/kg in 100ml saline
Study: NCT00226109
Drug: spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
Study: NCT04152577
Drug: R2-combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: R2-CHOP/CHOPE/DA-EPOCH/HD MTX~R2-CHOP :~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R2-DA-EPOCH:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R2-HD MTX:~lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1
Study: NCT04152577
Drug: R-combination chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP/CHOPE/DA-EPOCH/HD MTX~R-CHOP :~Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5~R-DA-EPOCH:~Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;~R-HD MTX:~Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1
Study: NCT01526330
Drug: YH14618
Approvals — FDA: no, EMA: no, PMDA: no
Description: A mg/disc
Study: NCT01526330
Drug: YH14618
Approvals — FDA: no, EMA: no, PMDA: no
Description: B mg/disc
Study: NCT01526330
Drug: YH14618
Approvals — FDA: no, EMA: no, PMDA: no
Description: C mg/disc
Study: NCT01526330
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg/disc
Study: NCT01349465
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
Study: NCT02571296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT03382925
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of normal saline to be used as steroid diluent in group #2 cervical interlaminar procedure.
Study: NCT04656223
Drug: FDC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: There is no treatment allocation. Patients administered FDC therapy by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT03878459
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PATIENTS WILL RECEIVE PLACEBO
Study: NCT02113436
Drug: FP/ SLM HFA MDI 50/25 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
Study: NCT03568474
Drug: Glass Ionomer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indirect pulp capping material
Study: NCT03664882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: tablet Route of administration: oral
Study: NCT00865059
Drug: NEURONTIN® 800 mg Tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
Study: NCT01860521
Drug: Drug used for analgesia procedures
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (Chirocaine®, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil®, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).
Study: NCT01860521
Drug: Drug used for termination of pregnancy procedure.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemeprost pessaries.
Study: NCT00629590
Drug: AzaSite®
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for \~12 days
Study: NCT00478179
Drug: Transdermal/Patch (Bupivacaine TTS [Eladur™])
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02214615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00695448
Drug: GSK1059615
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
Study: NCT00960661
Drug: Insulin/ Glargine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00984971
Drug: HEC Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied rectally
Study: NCT00843388
Drug: placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo tablet 25 mg OD
Study: NCT02413320
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02413320
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04492774
Drug: Steroid injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: epidural injections
Study: NCT04080622
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl 0,9% (IV infusion)
Study: NCT00914251
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of oral Placebo, 500 mg/daily
Study: NCT04168944
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill manufactured to mimic Lenvatinib 10mg tablet